Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Azizi

Vascular & Interventional Radiology Bell Gardens, CA Medical Doctor

NPI 1316101298 CMS profile 2789066

8218 Garfield Ave, Bell Gardens, CA 90201

Open in the dashboard

General payments

$200,446

180 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Azizi of Bell Gardens, CA is reported in the CMS Open Payments database as having received $200,446 across 180 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $21,594 5
2024 General $30,752 12
2023 General $39,254 42
2022 General $65,372 61
2021 General $41,224 30
2020 General $245 12
2019 General $2,004 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Azizi
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Robert Azizi were reported at $21,594. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Robert Azizi Vascular & Interventional Radiology median Middle half National median
2019 $2,004 $422 $125–$1,555 $163
2020 $245 $200 $68–$652 $114
2021 $41,224 $280 $99–$866 $132
2022 $65,372 $433 $137–$1,497 $149
2023 $39,254 $506 $152–$2,019 $160
2024 $30,752 $556 $175–$1,930 $164
2025 $21,594 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $195,240 88 payments
  2. Cardiovascular Systems Inc. $1,984 22 payments
  3. Nevro Corp. $670 7 payments
  4. Abbott Laboratories $521 18 payments
  5. Philips Electronics North America Corporation $469 8 payments
  6. Organogenesis Inc. $419 7 payments
  7. Boston Scientific Corporation $315 7 payments
  8. Bard Peripheral Vascular, Inc. $293 4 payments
  9. Medtronic, Inc. $144 5 payments
  10. Janssen Pharmaceuticals, Inc $135 6 payments
  11. Other $256 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Long term medical supply or device loan $150,667 7 payments
  2. Education $39,917 2 payments
  3. Food and Beverage $7,931 166 payments
  4. Travel and Lodging $1,932 5 payments
Products named General payments · program years 2019–2025
  1. Auryon Laser System 100-120 Vac Et $169,555 9 payments
  2. Auryon Laser System 100-120 Vac Cv $21,333 1 payment
  3. AURYON LASER SYSTEM 100-120 VAC Pad $4,257 77 payments
  4. Peripheral Orbital Atherectomy System $1,951 21 payments
  5. Senza $670 7 payments
  6. (6554) Peripheral Vascular Undivided $310 5 payments
  7. Puraply $184 3 payments
  8. Perclose ProGlide suture mediated closure system $179 3 payments
  9. PURAPLY WOUND MATRIX $164 2 payments
  10. Supera peripheral stent system $162 9 payments
  11. Other $1,466 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

200

Median for Diagnostic Radiology: 24

Drug cost

$41,130

Median for Diagnostic Radiology: $190

Branded share of claims

73%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 56 $39,037
Celecoxib Generic 37 $1,578
Clopidogrel Clopidogrel Bisulfate Brand 65 $345
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 25 $113
Cephalexin Generic 17 $57

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$13,159,145

Of which drugs: $12,338,981

Medicare patients

312

Average age 75

Services billed

11,831

199 women, 113 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 64%
Arthritis 64%
Depression 34%
Chronic kidney disease 31%
Ischemic heart disease 29%
Heart failure 24%
Osteoporosis 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

180 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record